Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MALVERN, PA., NOV. 20, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC., (NASDAQ: STIM) (THE COMPANY OR NEURONETICS) A VERTICALLY INTEGRATED, COMMERCIAL STAGE, MEDICAL TECHNOLOGY AND HEALTHCARE COMPANY WITH A STRATEGIC VISION OF TRANSFORMING THE LIVES OF PATIENTS WHENEVER AND WHEREVER THEY NEED HELP, WITH THE LEADING NEUROHEALTH THERAPIES IN THE WORLD, TODAY ANNOUNCED THAT THE MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE ON THURSDAY, DEC. 4, 2025. THE FIRESIDE CHAT IS SCHEDULED AT 12:30 P.M. (ET) THE SAME DAY. THE PRESENTATION WILL BE AVAILABLE VIA THE CONFERENCE PORTAL TO REGISTERED ATTENDEES.

NEURONETICS TO PARTICIPATE AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

NEW POLICY UPDATE BRINGS INNOVATIVE, NON-DRUG DEPRESSION TREATMENT TO ADOLESCENTS ACROSS 26 STATES NEW POLICY UPDATE BRINGS INNOVATIVE, NON-DRUG DEPRESSION TREATMENT TO ADOLESCENTS ACROSS 26 STATES

TRICARE WEST EXPANDS NEUROSTAR TMS COVERAGE TO INCLUDE ADOLESCENTS AGED 15+ STRUGGLING WITH DEPRESSION

DELIVERED $37.3 MILLION TOTAL REVENUE IN Q3 2025, REPRESENTING 11% ADJUSTED PRO FORMA REVENUE GROWTH VERSUS Q3 2024 GENERATED GREENBROOK CLINIC REVENUE OF $21.8 MILLION IN Q3 2025, AN INCREASE OF 25% ON AN ADJUSTED PRO FORMA BASIS VERSUS Q3 2024 CONTINUED CASH MANAGEMENT IMPROVEMENT, WITH CASH USED IN OPERATIONS OF $0.8 MILLION IN Q3 2025 STRENGTHENED BALANCE SHEET IN Q3 2025, ENDING THE QUARTER WITH $34.5 MILLION OF TOTAL CASH, CONSISTING OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH MALVERN, PA., NOV. 04, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC., (NASDAQ: STIM) (THE COMPANY OR NEURONETICS) A VERTICALLY INTEGRATED, COMMERCIAL STAGE, MEDICAL TECHNOLOGY AND HEALTHCARE COMPANY WITH A STRATEGIC VISION OF TRANSFORMING THE LIVES OF PATIENTS WHENEVER AND WHEREVER THEY NEED HELP, WITH THE LEADING NEUROHEALTH THERAPIES IN THE WORLD, TODAY ANNOUNCED ITS FINANCIAL AND OPERATING RESULTS FOR THE THIRD QUARTER OF 2025 AND THE INTENTION OF KEITH J.

NEURONETICS REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS AND ANNOUNCES CEO TRANSITION PLAN

MALVERN, PA., OCT. 31, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A COMMERCIAL STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON DESIGNING, DEVELOPING, AND MARKETING PRODUCTS THAT IMPROVE THE QUALITY OF LIFE FOR PATIENTS WHO SUFFER FROM NEUROHEALTH DISORDERS, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO TWELVE NEW EMPLOYEES AS DESCRIBED BELOW. IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4), THESE AWARDS WERE APPROVED BY NEURONETICS' COMPENSATION COMMITTEE AND MADE AS A MATERIAL INDUCEMENT TO THEIR RESPECTIVE EMPLOYMENT WITH THE COMPANY. IN ALL CASES, VESTING IS SUBJECT TO THE RECIPIENT'S CONTINUED SERVICE WITH THE COMPANY THROUGH THE APPLICABLE VESTING DATE, AND THE AWARDS ARE SUBJECT TO THE TERMS OF THE COMPANY'S 2020 INDUCEMENT INCENTIVE PLAN.

NEURONETICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

NEW COLLABORATION PROVIDES SERVICES TO STREAMLINE PATIENT SUPPORT, REDUCE ADMINISTRATIVE BURDEN, AND EXPAND ACCESS TO ADVANCED TMS TREATMENT ACROSS ELITE DNA CLINICS NEW COLLABORATION PROVIDES SERVICES TO STREAMLINE PATIENT SUPPORT, REDUCE ADMINISTRATIVE BURDEN, AND EXPAND ACCESS TO ADVANCED TMS TREATMENT ACROSS ELITE DNA CLINICS

NEURONETICS ANNOUNCES THREE-YEAR EXCLUSIVE PARTNERSHIP WITH ELITE DNA BEHAVIORAL HEALTH TO EXPAND NEUROSTAR ACCESS AND OPERATIONAL EXCELLENCE

MALVERN, PA., OCT. 21, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON DESIGNING, DEVELOPING, AND MARKETING PRODUCTS THAT IMPROVE THE QUALITY OF LIFE FOR PATIENTS WHO SUFFER FROM NEUROHEALTH DISORDERS AND THE MAKER OF NEUROSTAR ADVANCED THERAPY, THE LEADING PROVIDER OF TRANSCRANIAL MAGNETIC SIMULATION (TMS), ANNOUNCED THAT IT PLANS TO RELEASE THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS PRIOR TO MARKET OPEN ON TUESDAY, NOVEMBER 4, 2025. THE COMPANY WILL HOST A CONFERENCE CALL TO REVIEW ITS RESULTS AT 8:30 A.M. EASTERN TIME THE SAME DAY. THE CONFERENCE CALL WILL BE BROADCAST LIVE IN LISTEN-ONLY MODE VIA WEBCAST AT HTTPS://EDGE.MEDIA-SERVER.COM/MMC/P/YXRS8OSC . TO LISTEN TO THE CONFERENCE CALL ON YOUR TELEPHONE, PARTICIPANTS MAY REGISTER FOR THE CALL HERE . WHILE IT IS NOT REQUIRED, IT IS RECOMMENDED YOU JOIN 10 MINUTES PRIOR TO THE EVENT START.

NEURONETICS TO REPORT THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL

OVER 5 MILLION NEW YORK MEDICAID MEMBERS TO GAIN ACCESS TO TRANSCRANIAL MAGNETIC STIMULATION (TMS) SERVICES OVER 5 MILLION NEW YORK MEDICAID MEMBERS TO GAIN ACCESS TO TRANSCRANIAL MAGNETIC STIMULATION (TMS) SERVICES

NEW YORK STATE MEDICAID EXPANDS COVERAGE FOR TMS THERAPY, INCLUDING NEUROSTAR ADVANCED THERAPY, TO TREAT MAJOR DEPRESSIVE DISORDER (MDD)

MALVERN, PA., AUG. 06, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A COMMERCIAL STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON DESIGNING, DEVELOPING, AND MARKETING PRODUCTS THAT IMPROVE THE QUALITY OF LIFE FOR PATIENTS WHO SUFFER FROM NEUROHEALTH DISORDERS, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO SIX NEW EMPLOYEES AS DESCRIBED BELOW. IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4), THESE AWARDS WERE APPROVED BY NEURONETICS' COMPENSATION COMMITTEE AND MADE AS A MATERIAL INDUCEMENT TO THEIR RESPECTIVE EMPLOYMENT WITH THE COMPANY. IN ALL CASES, VESTING IS SUBJECT TO THE RECIPIENT'S CONTINUED SERVICE WITH THE COMPANY THROUGH THE APPLICABLE VESTING DATE, AND THE AWARDS ARE SUBJECT TO THE TERMS OF THE COMPANY'S 2020 INDUCEMENT INCENTIVE PLAN.

MALVERN, PA., AUG. 04, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A VERTICALLY INTEGRATED, COMMERCIAL STAGE, MEDICAL TECHNOLOGY AND HEALTHCARE COMPANY WITH A STRATEGIC VISION OF TRANSFORMING THE LIVES OF PATIENTS WHENEVER AND WHEREVER THEY NEED HELP, WITH THE LEADING NEUROHEALTH THERAPIES IN THE WORLD, TODAY ANNOUNCED THAT KEITH SULLIVAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE ON TUESDAY, AUGUST 12, 2025. THE COMPANY IS SCHEDULED TO PRESENT AT 1:30PM EASTERN TIME THE SAME DAY. THE PRESENTATION WILL BE AVAILABLE VIA THE CONFERENCE PORTAL TO REGISTERED ATTENDEES AND PRESENTING COMPANIES FOR 14 DAYS FOLLOWING THE EVENT. ABOUTNEURONETICS NEURONETICS, INC. BELIEVES THAT MENTAL HEALTH IS AS IMPORTANT AS PHYSICAL HEALTH. AS A GLOBAL LEADER IN NEUROSCIENCE, NEURONETICS IS DELIVERING MORE TREATMENT OPTIONS TO PATIENTS AND PHYSICIANS BY OFFERING EXCEPTIONAL IN-OFFICE TREATMENTS THAT PRODUCE EXTRAORDINARY RESULTS. NEUROSTAR ADVANCED THERAPY IS A NON-DRUG, NONINVASIVE TREATMENT THAT CAN IMPROVE THE QUALITY OF LIFE FOR PEOPLE SUFFERING FROM NEUROHEALTH CONDITIONS WHEN TRADITIONAL MEDICATION HAS NOT HELPED. IN ADDITION TO SELLING THE NEUROSTAR ADVANCED THERAPY SYSTEM AND ASSOCIATED TREATMENT SESSIONS TO CUSTOMERS, NEURONETICS OPERATES GREENBROOK TMS INC. (GREENBROOK) TREATMENT CENTERS ACROSS THE UNITED STATES, OFFERING NEUROSTAR ADVANCED THERAPY FOR THE TREATMENT OF MDD AND OTHER MENTAL HEALTH DISORDERS. NEUROSTAR ADVANCED THERAPY IS THE LEADING TMS TREATMENT FOR MDD IN ADULTS, WITH MORE THAN 7.4 MILLION TREATMENTS DELIVERED, AND IS BACKED BY THE LARGEST CLINICAL DATA SET OF ANY TMS TREATMENT SYSTEM FOR DEPRESSION, INCLUDING THE WORLD'S LARGEST DEPRESSION OUTCOMES REGISTRY. GREENBROOK TREATMENT CENTERS ALSO OFFER SPRAVATO (ESKETAMINE) NASAL SPRAY, A PRESCRIPTION MEDICINE INDICATED FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION (TRD) IN ADULTS AS MONOTHERAPY OR IN CONJUNCTION WITH AN ORAL ANTI

NEURONETICS TO PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

REAL-WORLD DATA SHOWING NEUROSTAR IS EFFECTIVE IN ADOLESCENTS AND YOUNG ADULTS WITH DEPRESSION FROM THE WORLD'S LARGEST TMS OUTCOMES DATASET REAL-WORLD DATA SHOWING NEUROSTAR IS EFFECTIVE IN ADOLESCENTS AND YOUNG ADULTS WITH DEPRESSION FROM THE WORLD'S LARGEST TMS OUTCOMES DATASET

Neuronetics, Inc.

STIM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Neuronetics, Inc.

STIM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

STIM